{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', '3.', 'A postdiscontinuation period - starts at the time of discontinuation from study treatment; this', 'period includes a summary (end-of-treatment) visit and will continue until death or the end of', 'study data collection.', 'Pre-treatment period', 'Treatment period', 'Postdiscontinuation period', 'Arm I (sunitinib + propranolol)', '(propranolol continuation if eligible)', 'Screening', 'Start of treatment', 'End of treatment', 'End of study', 'Figure 1. The illustration of study design for Protocol PS-001.', '3.2 Length of the Study', 'Total length of the study is planned to be at least 18 months, including 12 months of accrual time,', 'and then at least 6 months of follow-up time since the last patient recruitment.', '3.3 Study Extension', 'After data final analysis, all remaining on-study patients without disease progression will be', 'permitted to transition into the extension phase of the study to continue to receive treatment until', 'disease progression, death, unacceptable toxicity, patient refusal, or start of any new anticancer', 'treatment, whichever occurs first.', '4. Study Population', '4.1 Number of Patients Planned', 'According to the sample size calculation (Section 8.2), maximum number of 33 patients will be', 'enrolled in the study.', '4.2 Recruitment of Patients', 'Candidates for the trial will be recruited from a general population of patients with metastatic RCC,', 'who are planned to start first-line systemic anticancer therapy with sunitinib.', '4.3 Inclusion Criteria', 'Patients are eligible to be included in the study only if they meet all of the following criteria:', '1. Histological diagnosis of ccRCC or mixed-type RCC with more than 60% of clear-cell component.', '2. Diagnosis of stage IV RCC (primary metastatic or recurrence after surgical procedure).', '3. Prior nephrectomy (complete or partial).', 'Page 24 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', '4. Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)', 'version 1.1.', '5. Karnofsky performance status (KPS) score of 80-100%.', '6. Favourable- or intermediate-risk according to MSKCC criteria.', '7. Adequate organ function, including the following:', 'a.', 'hepatic: total bilirubin < 2 times the upper limit of normal (excluding patients with', 'Gilbert syndrome), aspartate aminotransferase (AST) and alanine aminotransferase (ALT)', '< 5 times the upper limit of normal,', 'b. renal: serum creatinine < 2 times the upper limit of normal,', 'c. bone marrow: absolute neutrophil count 1500/mm\u00b3, platelets 100000/mm\u00b3,', 'hemoglobin >9,5 g/dl.', '8. Normal thyroid function (natural or with supplementation of thyroid hormones) defined as', 'thyroid-stimulating hormone (TSH) within limits of normal.', '9. Age eighteen years or older on the day of consent.', '10. Written informed consent prior to study entry.', '4.4 Exclusion Criteria', 'Patients will be excluded from the study if they meet any of the following criteria:', '1. Prior systemic pharmacotherapy of renal cell carcinoma.', '2. Treatment with propranolol within 6 months of study entry.', '3.', 'Metastases in central nervous system (patients who had central nervous system metastases that', 'were surgically resected and/or treated with radiotherapy in the past and now are without', 'neurological symptoms, are allowed on protocol).', '4. Female patients who are pregnant or breast feeding or adults of reproductive potential who are', 'not using effective birth control methods.', '5. Presence of other malignancies (patients with carcinoma in situ of the cervix or basal cell', 'carcinoma of the skin are allowed on protocol).', '6.', 'Presence of any severe and/or uncontrolled medical conditions or other conditions that could', 'affect their participation in the study such as:', 'a. heart failure of New York Heart Association Class III or IV, significant cardiac arrhythmia', 'or any other clinically significant cardiovascular disease,', 'b. unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction', 'within 6 months of entering the study,', 'Page 25 of 60']\n\n###\n\n", "completion": "END"}